Concepedia

Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy

Chris Recknor, E. J. Czerwiński, Henry G. Bone, Sydney Lou Bonnick, Neil Binkley, Santiago Palacios, Alfred H. Moffett, Suresh Siddhanti, Irene Ferreira, Prayashi Ghelani,

Obstetrics and Gynecology · 2013 · 129 citations · 38 references

DOIFull text

Open access

Abstract

In postmenopausal women previously treated with a bisphosphonate and low BMD, denosumab treatment resulted in greater BMD increases than ibandronate at all measured sites. No new safety risks with denosumab treatment were identified.

References

38

Osteoporosis Prevention, Diagnosis, and Therapy

JAMA · 2001 · 5.4K citations

Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

David L. Lacey, Emma Timms, Hong‐Lin Tan et al. · Cell · 1998 · 5.4K citations · Full text

, , +13

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis

Robert M. Neer, Claude D. Arnaud, José Zanchetta et al. · New England Journal of Medicine · 2001 · 4.5K citations

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

Hisataka Yasuda, Nobuyuki Shima, N. Nakagawa et al. · Proceedings of the National Academy of Sciences · 1998 · 4.2K citations · Full text

, , +14

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures

Dennis M. Black, Steven R. Cummings, David Karpf et al. · The Lancet · 1996 · 3.8K citations

, , +5